Outcome in Hodgkin's Lymphoma Can Be Predicted from the Presence of Accompanying Cytotoxic and Regulatory T Cells

Purpose: Recent studies of Hodgkin's lymphoma (HL) have suggested that the presence of regulatory T cells in the reactive background may explain the inhibition of the antitumoral host immune response observed in these patients. This study aimed to assess the relevance of regulatory T cells and CTLs present in the background of HL samples in the prognosis of a series of classic HL (cHL) patients. Experimental Design: Expression of granzyme B and TIA-1 (markers for CTL) and FOXP3 (a marker for regulatory T cells) were evaluated independently by immunohistochemistry in tissue microarrays of 257 cHL patients and correlated with patient outcome. Results: The combined influence of the presence of FOXP3+ and TIA-1+ cells distinguished three risk groups of patients with 5-year overall survival of 100%, 88%, and 73%. The presence of a small number of FOXP3+ cells and a high proportion of TIA-1+ cells in the infiltrate represent an independent prognostic factor that negatively influenced event-free survival and disease-free survival in cHL. Compared with the features at diagnosis, relapsed samples tended to have more TIA-1+ cells and a lower proportion of FOXP3+ cells in the reactive background. Conclusions: These data suggest that low infiltration of FOXP3+ cells in conjunction with high infiltration of TIA-1+ cells in cHL may represent biological markers predicting an unfavorable outcome. Moreover, the variation of these markers over the course of the disease implies a possible role for them in the progression of HL cases.

[1]  Li Li,et al.  Conversion of Peripheral CD4+CD25− Naive T Cells to CD4+CD25+ Regulatory T Cells by TGF-β Induction of Transcription Factor Foxp3 , 2003, The Journal of experimental medicine.

[2]  S. Pileri,et al.  High‐throughput tissue microarray analysis of G1‐cyclin alterations in classical Hodgkin's lymphoma indicates overexpression of cyclin E1 , 2003, The Journal of pathology.

[3]  T. Mak,et al.  The role of cytokines in classical Hodgkin lymphoma. , 2002, Blood.

[4]  R. Barker,et al.  Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. , 2004, Blood.

[5]  T. Mak,et al.  Immunologic Self-Tolerance Maintained by Cd25+Cd4+Regulatory T Cells Constitutively Expressing Cytotoxic T Lymphocyte–Associated Antigen 4 , 2000, The Journal of experimental medicine.

[6]  A. Rudensky,et al.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells , 2003, Nature Immunology.

[7]  P. Chrobak.  Control of T cell responses, tolerance and autoimmunity by regulatory T cells: current concepts. , 2003, Acta medica.

[8]  R. Offringa,et al.  Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[9]  E. Shevach,et al.  Cutting Edge: Control of CD8+ T Cell Activation by CD4+CD25+ Immunoregulatory Cells , 2001, The Journal of Immunology.

[10]  J. Nicolas,et al.  Innate CD4+CD25+ regulatory T cells are required for oral tolerance and inhibition of CD8+ T cells mediating skin inflammation. , 2003, Blood.

[11]  H. Moch,et al.  Tissue microarrays for rapid linking of molecular changes to clinical endpoints. , 2001, The American journal of pathology.

[12]  A. van den Berg,et al.  Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  Wei-Zen Wei,et al.  Anti-tumor immunity and autoimmunity: a balancing act of regulatory T cells , 2004, Cancer Immunology, Immunotherapy.

[14]  A. van den Berg,et al.  Interaction between host T cells and Reed-Sternberg cells in Hodgkin lymphomas. , 2000, Seminars in cancer biology.

[15]  P. V. van Diest,et al.  Activated cytotoxic T cells as prognostic marker in Hodgkin's disease. , 1997, Blood.

[16]  P. Anderson,et al.  A monoclonal antibody reactive with a 15-kDa cytoplasmic granule-associated protein defines a subpopulation of CD8+ T lymphocytes. , 1990, Journal of immunology.

[17]  Anthony D Kelleher,et al.  Identification of circulating antigen-specific CD4+ T lymphocytes with a CCR5+, cytotoxic phenotype in an HIV-1 long-term nonprogressor and in CMV infection. , 2004, Blood.

[18]  C. Meijer,et al.  Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system? , 2002, Blood.

[19]  Juan F. García,et al.  Influence of biologic markers on the outcome of Hodgkin's lymphoma: a study by the Spanish Hodgkin's Lymphoma Study Group. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  A. van den Berg,et al.  Immune reactions in classical Hodgkin's lymphoma. , 1999, Seminars in hematology.

[21]  T. Ley,et al.  Natural killer and lymphokine-activated killer cells require granzyme B for the rapid induction of apoptosis in susceptible target cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[22]  S. Zheng,et al.  The role of the combination of IL‐2 and TGF‐β or IL‐10 in the generation and function of CD4+ CD25+ and CD8+regulatory T cell subsets , 2003, Journal of leukocyte biology.

[23]  J. Armitage,et al.  A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. , 1998, The New England journal of medicine.

[24]  J. Trapani,et al.  Cutting Edge: Granzymes A and B Are Not Essential for Perforin-Mediated Tumor Rejection , 2003, The Journal of Immunology.

[25]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[26]  T. Ley,et al.  How do lymphocytes kill tumor cells? , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  N. Câmara,et al.  Human CD4+CD25+ regulatory cells have marked and sustained effects on CD8+ T cell activation , 2003, European journal of immunology.

[28]  J. Teruya-Feldstein,et al.  Application of tissue microarray technology to the study of non-Hodgkin's and Hodgkin's lymphoma. , 2002, Human pathology.

[29]  Olker,et al.  A PROGNOSTIC SCORE FOR ADVANCED HODGKIN ’ S DISEASE , 2000 .

[30]  R. Flavell,et al.  CD4+CD25+ T regulatory cells control anti-islet CD8+ T cells through TGF-β–TGF-β receptor interactions in type 1 diabetes , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[31]  K. Ohshima,et al.  Human and viral interleukin‐10 in Hodgkin's disease, and its influence on CD4+ and CD8+ T lymphocytes , 1995, International journal of cancer.

[32]  Lydia Sánchez,et al.  Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. , 2003, Blood.

[33]  O. Kallioniemi,et al.  Tissue microarray technology for high-throughput molecular profiling of cancer. , 2001, Human molecular genetics.

[34]  S. Wahl,et al.  TGF-β: the missing link in CD4+CD25+ regulatory T cell-mediated immunosuppression , 2003 .

[35]  T. Schumacher,et al.  Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses , 2001, The Journal of experimental medicine.

[36]  M. Steurer,et al.  Increase of regulatory T cells in the peripheral blood of cancer patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  E. Shevach,et al.  CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. , 1998, Journal of immunology.

[38]  T. Nomura,et al.  Control of Regulatory T Cell Development by the Transcription Factor Foxp3 , 2002 .

[39]  S. Poppema,et al.  Absence of HLA class I expression by Reed-Sternberg cells. , 1994, The American journal of pathology.

[40]  Paul Anderson,et al.  A polyadenylate binding protein localized to the granules of cytolytic lymphocytes induces DNA fragmentation in target cells , 1991, Cell.

[41]  H. Hirai,et al.  Human CD4+ CD25+ regulatory T cells suppress NKT cell functions. , 2003, Cancer research.

[42]  V. Diehl,et al.  L-428 nodular sclerosing Hodgkin's cell secretes a unique transforming growth factor-beta active at physiologic pH. , 1988, The Journal of clinical investigation.

[43]  Larry V McIntire,et al.  Automated Selection of DAB-labeled Tissue for Immunohistochemical Quantification , 2003, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[44]  B. Rouse,et al.  CD4+CD25+ T Cells Regulate Virus-specific Primary and Memory CD8+ T Cell Responses , 2003, The Journal of experimental medicine.

[45]  J. Shimizu,et al.  Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance , 2002, Nature Immunology.